SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 198.69+2.0%Dec 18 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (24561)8/15/1998 10:09:00 PM
From: Machaon  Read Replies (1) of 32384
 
Henry, this was from the August 12th news release about the Seragen merger:

<==================================================================>
"The Company is working to strengthen its position in CTCL and other non-Hodgkin's lymphoma therapies by filing New Drug Applications for Targretin capsules (bexarotene) and Targretin gel (bexarotene) 1.0% in late 1998 or early 1999."
<==================================================================>

You have probably already answered this, but, if Ligand files these two NDAs in early 1999, when would you expect FDA action on them?

TIA, Bob
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext